Chris Cargill, Sosei Heptares president and CEO
November 27, 2023 07:14 AM EST
Deals

So­sei Hep­tares to take back GPCR ag­o­nist af­ter GSK changes course

Katherine Lewin

News Reporter

So­sei Hep­tares says it will con­tin­ue to de­vel­op its ear­ly-stage oral GPR35 ag­o­nist af­ter GSK gave the drug back fol­low­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times